Interpace Q3 revenue $8.2M (+2%), adjusted EBITDA positive; going concern removed

INTERPACE BIOSCIENCES, INC.

2023-Q3 EPS reported -$4.82 revenue$5,678,000

Q3 revenue $8.2M, up 2% YoY; gross margin improved to 58% from 55%.
Adjusted EBITDA positive $0.1M vs -$0.2M prior year; loss from continuing ops $1.3M.
Cash balance $6.3M (up from $3.2M); sale of Pharma business removed going concern.
ThyGeNEXT pricing change reduced revenue and EBITDA by ~$1.4M in Q3.
Nine-month revenue $23.5M (-2%); loss from continuing ops improved to -$4.5M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INTERPACE BIOSCIENCES, INC. reported the quarter ended September 30, 2022 results: revenue $8.2 million.

Period: the quarter ended September 30, 2022
Revenue: $8.2 million
Result: reported results

Exact text from the filing

Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern ● Q3 Revenue of $8.2 million up 2% versus Prior Year ● Q3 Adjusted EBITDA Positive ● Cash and Cash Equivalents total $6.3 million as of September 30, 2022 PARSIPPANY, NJ, November 14, 2022 (GLOBE NEWSWIRE)

View on SEC.gov

Browse all earnings releases →

INTERPACE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-22-032187

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.